
Overview
Animal health company's preliminary Q4 sales declined 1.6% yr/yr
Domestic sales rose 8.7%, while international sales fell 52.6%
Outlook
Company focuses on expanding First Defense capacity after pausing Re-Tain investment
ImmuCell plans manufacturing improvements to support First Defense growth targets
Result Drivers
TRI-SHIELD GROWTH - Tri-Shield sales increased by 41.3%, driven by new dairy and beef customers, according to CEO Olivier te Boekhorst
INTERNATIONAL SALES DECLINE - International sales fell 52.6% due to order timing, per CEO Olivier te Boekhorst
STRATEGIC SHIFT - Focus on First Defense after FDA issues with Re-Tain, resulting in a $2.9 mln write-down
Key Details
Metric | Beat/Miss | Actual | Consensus Estimate |
Q4 Product Sales |
| $7.60 mln |
|
Press Release: ID:nGNX2gDkM2
For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com.